In today’s recent session, 0.54 million shares of the Unicycive Therapeutics Inc (NASDAQ:UNCY) have been traded, and its beta is 2.42. Most recently the company’s share price was $0.69, and it changed around $0.05 or 7.81% from the last close, which brings the market valuation of the company to $25.76M. UNCY at last check was trading at a discount to its 52-week high of $1.82, offering almost -163.77% off that amount. The share price’s 52-week low was $0.47, which indicates that the recent value has risen by an impressive 31.88% since then. We note from Unicycive Therapeutics Inc’s average daily trading volume that its 3-month average coming to 392.64K.
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
Instantly UNCY has been showing a green trend so far today with a performance of 7.81% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -21.06% year-to-date, but still up 5.56% over the last five days. On the other hand, Unicycive Therapeutics Inc (NASDAQ:UNCY) is -31.84% down in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
Unicycive Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 19.17 percent over the past six months and at a -93.33% annual growth rate that is well below the industry average of 13.30%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -77.09%.
UNCY Dividends
Unicycive Therapeutics Inc’s next quarterly earnings report is expected to be released in July.
